Targeted diagnostics GenPro is developing immune system–focused epigenomic blood tests (EpiMarkers) for oncology and non-oncology diseases, starting with Endometriosis. This presents a sales opportunity to partner with diagnostics firms and biopharma seeking disruptive, non-invasive diagnostic solutions with potential to reduce invasive procedures and healthcare costs.

Cooperative partnerships Business model centers on collaborative development and licensing with biopharma, molecular diagnostics, and genomic testing companies. This suggests sales outreach should emphasize flexible co-development timelines, licensing options, and joint go‑to‑market strategies to align with partner goals.

Speed to market GenPro aims to operationalize immuno-EpiMarkers into commercial tests within approximately 18 months per partner. There is a strong opportunity to position GenPro as a rapid‑delivery partner for mid‑to‑late stage diagnostics programs needing faster proof of concept and regulatory pathways.

High‑impact disease focus The initial pipeline target Endometriosis addresses a large, underserved market with substantial diagnostic gaps and costly current practices. Partnerships could target payer and patient access advantages by showcasing noninvasive, accurate testing to drive adoption and reduce overall care costs.

Market reach and credibility In a landscape with established players like NeoGenomics, Tempus, and Guardant Health, GenPro can pursue opportunities to license or co-develop tests that complement existing workflows (blood-based Epigenetic profiling), offering unique immune‑response biomarkers and wet‑lab integration for scalable deployments.